Excited to see our COMPANION-002 trial published in JCO and presented at #ESMO26!

ilyas sahin, MD· @ilyassahinMD · X·2026-10-24 19:33· 18 小时前评分70

正文 · 原文

Treatment options remain limited for advanced biliary tract cancer after first-line therapy, especially without targetable mutations.

Tovecimig + paclitaxel vs paclitaxel alone:

• Tumor response (ORR): 18% vs 5.3%
• Time without progression (median PFS): 4.7 vs 2.6 months (HR 0.44)

Proud to have contributed to this multicenter trial!

219 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2878RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study

https://esmocongress.esmo.org

543RO按 Rapid oral: Breast cancer, early stage 对上

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (

https://esmocongress.esmo.org

LBA37按 Proffered paper: Gynaecological cancers 对上

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org

引用@

‼️ #ESMO26 simultaneous publication by Azad, et al. COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer Read full publication: https://bit.ly/4i2ZdwI

在 X 查看被引用的帖子

来源：ilyas sahin, MD · x.com